Get the full picture
Sign in to uncover key details.
Angiex
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
150 Cambridgepark Dr Fl 5, Cambridge, Ma...Phone Number
(617) 576-1753Website
www.angiex.comRevenue
<$5 MillionIndustry
About Angiex
Angiex is a biotechnology company focused on developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) aimed at addressing the critical challenges of cancer lethality. Their innovative Nuclear Delivery Platform targets tumor cells and endothelial cells in tumor blood vessels, promising enhanced efficacy for solid cancer treatments. The company's lead product, AGX101, is set to enter clinical trials, with a pipeline of additional ND-ADCs in development. Angiex seeks to partner with high-quality collaborators to advance their mission of making cancer a non-lethal disease.Explore more
Angiex Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Angiex
Compare insights from companies similar to Angiex, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Angiex Tech Stack
A closer look at the technologies used by Angiex
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Angiex
Sign Up For FreeTo access detailed company insights
Angiex is a biotechnology company focused on developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) aimed at addressing the critical challenges of cancer lethality. Their innovative Nuclear Delivery Platform targets tumor cells and endothelial cells in tumor blood vessels, promising enhanced efficacy for solid cancer treatme... Read More
